JPRN-UMIN000010429
Completed
N/A
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancer - Exploratory study in achievement of improved survival by molecular targeted chemotherapy and liver resection for not optimally resectable colorectal liver metastases
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer
- Sponsor
- EPS Corporation
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab.solid cancerJPRN-UMIN000028474Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.30
Completed
N/A
The exploratory study to evaluate biomarkers in prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer (J-TAIL-2)on-small cell lung cancer or extensive disease small cell lung cancerJPRN-UMIN000043663CHUGAI PHARMACEUTICAL CO., LTD.450
Recruiting
N/A
A biomarker assessment study to investigate the influence of high-frequency chest wall oscillations on the clearance of cerebrospinal fluid biomarkersNL-OMON51372Centre for Human Drug Research34
Recruiting
N/A
Investigating the use of biomarkers to predict pregnancy and long term complications in women who develop elevated blood pressure, gestational diabetes, fetal growth restriction or spontaneous preterm labour during pregnancyACTRN12622001450707ational Heart Foundation600
Active, Not Recruiting
Phase 1
Biomarkermoderate-to-severe psoriasisMedDRA version: 19.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-002588-40-DEniversity Hospital Schleswig-Holstein40